Sanofi launches generic version of arthritis drug Arava in USA

French drug major Sanofi (Euronext: SAN) launched the generic version of Arava (leflunomide) tablets to treat rheumatoid arthritis (RA), through its US generics unit.

For people living with rheumatoid arthritis, leflunomide blocks autoimmune antibodies that reduce inflammation with the aim of improving mobility. Sanofi's authorized generic version is the same formulation as the branded Arava, for which the company holds the original patent.

Cary Yonce, vice president, general therapeutics and life cycle management, Sanofi, said: "The Arava authorized generic assures patients that they receive the same quality treatment of the original drug. We are committed to making authorized generics like Arava available and affordable to patients who need them."